Home Cart Sign in  
Chemical Structure| 953769-46-5 Chemical Structure| 953769-46-5

Structure of Sotuletinib
CAS No.: 953769-46-5

Chemical Structure| 953769-46-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

BLZ945 is a highly selective and brain-penetrant inhibitor of CSF1R with IC50 of 1 nM and > 3200-fold higher than its affinity for other kinases.

Synonyms: BLZ945

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Sotuletinib

CAS No. :953769-46-5
Formula : C20H22N4O3S
M.W : 398.48
SMILES Code : O=C(NC)C1=NC=CC(OC2=CC=C3N=C(N[C@H]4[C@H](O)CCCC4)SC3=C2)=C1
Synonyms :
BLZ945
MDL No. :MFCD28142668
InChI Key :ADZBMFGQQWPHMJ-RHSMWYFYSA-N
Pubchem ID :46184986

Safety of Sotuletinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Sotuletinib

RTK

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
M1 macrophages 30 ng/ml To investigate the effects of exosomes on M1 macrophages and assess polarization towards an M2-like phenotype. PMC7178595

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Indian rhesus macaques SIVmac251 infection model Oral 10 mg/kg/day or 30 mg/kg/day Once daily for 20-30 days To investigate the effects of BLZ945 on brain macrophages during acute SIV infection, results showed that high-dose BLZ945 significantly reduced the number of CD163 and CD206 positive cells in the brain and significantly decreased viral DNA loads in multiple brain regions. PMC11370798

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT04066244 Amyotrophic Lateral Sclerosis PHASE2 TERMINATED 2024-02-01 Yale University School of Medi... More >>cine, New Haven, Connecticut, 06520-8048, United States|Massachusetts General Hospital ., Boston, Massachusetts, 02114, United States|Novartis Investigative Site, Herston, Queensland, 4029, Australia|Novartis Investigative Site, Cauldfield, Victoria, 3162, Australia|Novartis Investigative Site, Heidelberg, Victoria, 3084, Australia|Novartis Investigative Site, Turku, 20520, Finland|Novartis Investigative Site, Stockholm, 14186, Sweden Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.51mL

0.50mL

0.25mL

12.55mL

2.51mL

1.25mL

25.10mL

5.02mL

2.51mL

 

Historical Records

Categories